6,7-Dihydropyrazolo[1,5-a]pyrazin-4(5H)-one Derivatives as mGluR2 Negative Allosteric Modulators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological disorders such as mood disorders, cognitive impairments, and psychotic disorders involving metabotropic glutamate receptor subtype 2 (mGluR2) lack effective negative allosteric modulators that can specifically target these conditions without significant side effects.
Innovation Solution
Development of 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) that selectively interact with the mGluR2 receptor, modulating glutamatergic signaling to alleviate symptoms of these disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for neurological disorders are used, then therapeutic effects are achieved, but significant side effects occur
Solution Approach 1:
The patent develops compounds with selective affinity for mGluR2 receptors, achieving localized modulation of glutamatergic signaling specifically at this receptor subtype. The compounds exhibit preferential binding to mGluR2 over other receptor types, allowing therapeutic effects to be achieved with minimal off-target effects and reduced side effects.
Solution Approach 2:
The patent employs negative allosteric modulation rather than direct orthosteric antagonism, fundamentally changing the mechanism of action. This allosteric approach modifies the receptor's conformational state to reduce glutamate binding affinity and efficacy, providing a more nuanced modulation that achieves therapeutic benefits with improved safety profiles compared to traditional antagonists.
2Reliability
If mGluR2 receptor modulation is achieved, then glutamatergic signaling is attenuated, but selectivity for specific neurological conditions must be maintained
Solution Approach 1:
The compounds are designed with specific molecular features that confer selectivity for mGluR2 receptors over other metabotropic glutamate receptor subtypes. This selective binding allows the drugs to modulate glutamatergic signaling in a targeted manner, addressing specific neurological conditions without broadly affecting other neurotransmitter systems.
Solution Approach 2:
The patent uses negative allosteric modulators as intermediary molecules that indirectly regulate glutamatergic signaling. Rather than directly blocking the glutamate binding site, these compounds bind to allosteric sites and modulate receptor activity, providing a more selective and tunable approach to treating neurological disorders.
Data Source
AI summary
The present invention relates to novel 6,7-dihydropyrazolo[1,5-α]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ("mGluR2"). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.